Affinage

SIGLEC10

Sialic acid-binding Ig-like lectin 10 · UniProt Q96LC7

Length
697 aa
Mass
76.6 kDa
Annotated
2026-04-28
53 papers in source corpus 21 papers cited in narrative 20 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

Siglec-10 is an inhibitory sialic acid–binding immunoglobulin-like lectin that broadly dampens innate and adaptive immune responses by transducing inhibitory signals through cytoplasmic ITIM-mediated recruitment of SHP-1 and SHP-2 phosphatases. Its N-terminal domain 1 recognizes α2,3- and α2,6-sialylated glycans through a selectivity-determining CC' loop and dual arginine residues (R119, R127), while domain 2 mediates functionally required homodimerization (PMID:41747717, PMID:11284738). Engagement of diverse sialylated ligands—including CD24 (which bridges DAMPs such as HMGB1 to suppress NF-κB signaling), soluble CD52 (which inhibits TCR-proximal Lck/ZAP-70 phosphorylation), integrin α3β1 on tumor cells, and bacterial pseudaminic acid—triggers ITIM phosphorylation and SHP-1 recruitment, suppressing macrophage phagocytosis, T cell activation, and proinflammatory cytokine production (PMID:19264983, PMID:23685786, PMID:29997173, PMID:41182080, PMID:38372418). Tumor-expressed CD24 and integrin α3β1 exploit this checkpoint to evade macrophage-mediated clearance, and genetic ablation or antibody blockade of the CD24–Siglec-10 or α3β1–Siglec-10 axis restores phagocytosis and reduces tumor growth in vivo (PMID:31367043, PMID:41182080).

Mechanistic history

Synthesis pass · year-by-year structured walk · 10 steps
  1. 2001 High

    Establishing Siglec-10 as an inhibitory sialic acid–binding receptor resolved its molecular identity: cDNA cloning revealed a type I transmembrane protein with five Ig-like domains and cytoplasmic ITIMs that bind sialic acid–bearing ligands, while biochemical analysis showed that ITIM tyrosines Y597/Y667 are phosphorylated and recruit SHP-1 and SHP-2 phosphatases.

    Evidence cDNA cloning, erythrocyte/sialoglycoconjugate binding assays, in vitro kinase assays with Y→F mutants, and cell-extract pulldowns across three independent studies

    PMID:11284738 PMID:11358961 PMID:11733002

    Open questions at the time
    • No endogenous physiological ligand identified
    • Downstream signaling consequences in primary immune cells not yet tested
    • Three-dimensional structure unknown
  2. 2002 High

    Fine-mapping of the SHP-1 docking site to ITIM Y609 and the N-terminal SH2 domain of SHP-1 refined the signaling model and showed that Siglec-10 does not engage SAP/SH2D1A, distinguishing its signaling from SLAM-family receptors.

    Evidence Yeast three-hybrid cloning, site-directed mutagenesis of ITIM tyrosines, Western blot

    PMID:12163025

    Open questions at the time
    • Physiological context of SHP-1 recruitment (which cell types, which stimuli) not defined
    • Relative contributions of Y597, Y609, Y667 to signaling in intact cells unresolved
  3. 2009 High

    Identification of two physiological ligands—CD24 and VAP-1—placed Siglec-10 in distinct immunological contexts: CD24 bridges DAMPs (HMGB1, HSP70, HSP90) to Siglec-10/Siglec-G to selectively suppress danger-associated NF-κB activation, while VAP-1 on inflamed endothelium engages Siglec-10 on leukocytes to modulate adhesion and hydrogen peroxide production.

    Evidence Co-IP plus Siglec-G-KO/CD24-KO genetic epistasis in mice and NF-κB reporter assays (CD24); phage display, adhesion assays, and enzymatic H₂O₂ assays (VAP-1)

    PMID:19264983 PMID:19861682

    Open questions at the time
    • Sialic acid dependence of CD24–Siglec-10 binding not formally demonstrated in this study
    • In vivo consequence of VAP-1–Siglec-10 axis on leukocyte trafficking not assessed
  4. 2013 High

    Discovery that soluble CD52 released from CD52hi T cells suppresses T cell activation by engaging Siglec-10 and inhibiting Lck/ZAP-70 phosphorylation established a non-Treg mechanism of T cell regulation.

    Evidence Binding assays, phosphokinase assays, T cell suppression assays, adoptive transfer in NOD mice

    PMID:23685786

    Open questions at the time
    • Whether CD52–Siglec-10 interaction is sialic acid–dependent was not molecularly defined
    • Contribution of HMGB1 bridging to this interaction was not explored until later
  5. 2018 High

    Mechanistic dissection of the CD52–HMGB1–Siglec-10 signaling complex showed that CD52's α2,3-sialylated N-glycan binds Siglec-10 only after CD52 engages HMGB1's Box B domain, triggering ITIM phosphorylation, SHP-1 recruitment, and Siglec-10 association with the TCR to suppress T cell function.

    Evidence CD52-Fc domain-mapping binding assays, anti-HMGB1 blockade, Co-IP of the quaternary complex (CD52–HMGB1–Siglec-10–SHP-1–TCR), tyrosine phosphorylation assay

    PMID:29997173

    Open questions at the time
    • Structural basis of HMGB1-facilitated glycan presentation to Siglec-10 unknown
    • Stoichiometry of the multiprotein complex not determined
  6. 2019 High

    Demonstrating that tumor-expressed CD24 exploits Siglec-10 on macrophages as a 'don't-eat-me' signal to evade phagocytosis established Siglec-10 as an innate immune checkpoint in cancer, with therapeutic blockade reducing tumor growth in vivo.

    Evidence CRISPR knockout of CD24 or Siglec-10, monoclonal antibody blockade, phagocytosis assays, xenograft mouse models

    PMID:31367043

    Open questions at the time
    • Whether the anti-phagocytic effect requires SHP-1/SHP-2 signaling specifically was not tested
    • Relative importance of CD24 vs. other sialylated ligands on tumor cells not delineated
  7. 2014 Medium

    Bacterial pseudaminic acid on Campylobacter jejuni flagella was identified as a microbial ligand for Siglec-10, revealing that pathogens can co-opt inhibitory Siglec signaling to induce IL-10 via p38 MAPK and dampen dendritic cell responses; subsequent work mapped the critical 7-N-acetyl group on pseudaminic acid and showed suppression of macrophage phagocytosis.

    Evidence Isogenic bacterial mutants, Siglec-10 overexpression, p38 inhibitor experiments (2014); carbohydrate-receptor binding assays identifying 7-N-acetyl group, IL-10 secretion and phagocytosis assays (2024)

    PMID:24823621 PMID:38372418

    Open questions at the time
    • Pseudaminic acid–Siglec-10 structural complex not determined
    • In vivo relevance of this axis during natural infection not established
  8. 2023 Medium

    Identification of PU.1 as a direct transcriptional activator of SIGLEC10 in macrophages defined a regulatory mechanism controlling checkpoint expression; PU.1 knockdown reduced Siglec-10 levels, enhanced phagocytosis, and inhibited glioma growth in vivo.

    Evidence ChIP, luciferase reporter assay, PU.1 knockdown with RNA-seq/qRT-PCR/Western blot, in vivo tumor models

    PMID:41115355

    Open questions at the time
    • Whether PU.1 is the sole or dominant transcriptional regulator of Siglec-10 is not established
    • Post-transcriptional regulation of Siglec-10 surface expression unexplored
  9. 2025 High

    Identification of integrin α3β1 as a sialylated glycoprotein ligand for Siglec-10 on pancreatic cancer cells expanded the don't-eat-me ligand repertoire beyond CD24; antibody blockade of this interaction restored macrophage phagocytosis and reduced PDAC tumor growth across xenograft and transgenic models.

    Evidence Ligand identification, Co-IP/pulldown, monoclonal antibody blockade, phagocytosis assays, PDAC xenograft and Siglec-10 transgenic mouse models

    PMID:41182080

    Open questions at the time
    • Specific sialoglycan structures on α3β1 that engage Siglec-10 not identified
    • Whether α3β1-mediated immune evasion operates in cancer types beyond PDAC is untested
  10. 2026 High

    Crystal structures of Siglec-10 revealed how domain 1's CC' loop confers ligand selectivity for both α2,3- and α2,6-sialylated glycans, identified dual arginine residues (R119, R127) in the binding site, and showed that D2-mediated homodimerization is functionally required for cellular glycan recognition; CD24 knockout did not abolish binding to breast cancer cells, indicating a broader glycoprotein ligand repertoire.

    Evidence X-ray crystallography, STD-NMR, mutagenesis of CC' loop and D2 interface, cellular binding assays, CD24 knockout

    PMID:41747717

    Open questions at the time
    • Structural basis of Siglec-10 interaction with specific glycoprotein ligands (e.g., integrin α3β1, CD52–HMGB1 complex) not captured
    • Functional significance of homodimerization for ITIM signaling not tested
    • Identity of the dominant non-CD24 sialylated ligands on breast cancer cells remains unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • Outstanding questions include the structural basis of Siglec-10 engagement with intact glycoprotein ligands (CD24, CD52–HMGB1, α3β1), the relative contribution of individual ITIM tyrosines to SHP-1/SHP-2 recruitment in primary immune cells, how homodimerization couples to intracellular signaling, and whether therapeutic disruption of specific ligand–Siglec-10 pairs can achieve tumor-selective immune activation without systemic autoimmunity.
  • No co-crystal structure of Siglec-10 with any glycoprotein ligand
  • In vivo functional consequences of D2 dimerization interface mutations unknown
  • Therapeutic window for Siglec-10 blockade vs. autoimmune risk not defined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0008289 lipid binding 4 GO:0060089 molecular transducer activity 4 GO:0098772 molecular function regulator activity 3
Localization
GO:0005886 plasma membrane 5
Pathway
R-HSA-168256 Immune System 7 R-HSA-162582 Signal Transduction 4 R-HSA-1643685 Disease 3
Partners
CD24CD52HMGB1ITGA3ITGB1SHP-1SHP-2VAP-1

Evidence

Reading pass · 20 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2001 Siglec-10 is a type I transmembrane protein with five extracellular Ig-like domains and a cytoplasmic tail containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs); it mediates sialic acid-dependent binding to human erythrocytes and soluble sialoglycoconjugates, establishing it as an inhibitory lectin receptor. cDNA cloning, binding assays with erythrocytes and sialoglycoconjugates, flow cytometry The Biochemical journal High 11284738 11358961 11733002
2001 The ITIM tyrosines Y597 and Y667 in the Siglec-10 cytoplasmic tail are phosphorylated by tyrosine kinases; SHP-1 interacts with Y667 and SHP-2 interacts with Y667 and at least one additional tyrosine, establishing Siglec-10 as an inhibitory receptor that recruits SHP phosphatases. In vitro kinase assay with wild-type and Y→F mutant cytoplasmic domain constructs; cell extract pulldown assays European journal of biochemistry High 11733002
2002 Siglec-10 recruits SHP-1 to its cytoplasmic tail in a tyrosine phosphorylation-dependent manner; mutational analysis identified ITIM Y609 of Siglec-10 and the N-terminal SH2 domain of SHP-1 as critical for this interaction. Siglec-10 does not bind SAP/SH2D1A, distinguishing the CD150-like motif as a docking site for other mediators. Yeast three-hybrid cloning of splice variant, Western blot, site-directed mutagenesis of ITIM tyrosines Biochemical and biophysical research communications High 12163025
2009 CD24 associates with the DAMPs HMGB1, HSP70, and HSP90 and negatively regulates their stimulatory activity; CD24 interaction with Siglec-10 (Siglec-G in mice) inhibits NF-κB activation and selectively suppresses danger-associated (but not pathogen-associated) innate immune responses. Co-immunoprecipitation, CD24-deficient mouse models, NF-κB reporter assays, genetic epistasis (CD24/Siglec-G double knockout) Science High 19264983
2009 Siglec-10 on leukocytes binds VAP-1 (vascular adhesion protein-1) on inflamed endothelium, identified by phage display; this interaction was verified by adhesion assays and molecular modeling. Siglec-10 serves as a substrate for VAP-1's amine oxidase activity, leading to increased hydrogen peroxide production, implicating the Siglec-10–VAP-1 axis in lymphocyte adhesion and modulation of the inflammatory microenvironment. Phage display screening, adhesion assays, molecular modeling, hydrogen peroxide production assay Blood High 19861682
2013 Soluble CD52 released by phospholipase C from CD52hi T cells binds Siglec-10 on T cells and impairs phosphorylation of TCR-associated kinases Lck and ZAP-70, thereby suppressing T cell activation. This defines a ligand-receptor mechanism of T cell regulation distinct from Foxp3+ Tregs. Binding assay (soluble CD52-Siglec-10), phosphokinase assays (Lck, ZAP-70), T cell suppression assays, adoptive transfer in NOD mice Nature immunology High 23685786
2014 Campylobacter jejuni flagella bearing pseudaminic acid residues bind Siglec-10 on dendritic cells; overexpression of Siglec-10 in cells infected with C. jejuni increased IL-10 production in a p38 MAPK-dependent manner, defining a novel flagellin-Siglec-10 immune modulatory axis. C. jejuni isogenic mutant analysis, Siglec-10 overexpression in cells, p38 inhibitor experiments, flow cytometry The Journal of infectious diseases Medium 24823621
2016 Placental CD24 interacts with Siglec-10 via terminal sialic acid glycan residues in an EDTA-sensitive manner; CD24 did not interact with Siglec-3 or Siglec-5, establishing specificity. Co-localization of CD24 and Siglec-10 was observed at the fetal-maternal interface, suggesting a role in immune tolerance during pregnancy. Affinity purification of placental CD24, ELISA binding assays, EDTA inhibition, immunohistochemistry, immunofluorescence co-localization Histochemistry and cell biology Medium 28012129
2017 Porcine Siglec-10 functions as an alternative receptor for PRRSV; Siglec-10-expressing cells showed significantly enhanced PRRSV infection in a CD163-dependent manner, and Siglec-10 was demonstrated to mediate endocytosis of PRRSV, establishing its role in viral entry. Transfection of Siglec-10 into PK15-CD163 cells, virus infection assays, TCID50 measurement, endocytosis assays The Journal of general virology Medium 28742001
2018 Soluble CD52 binds specifically to the proinflammatory Box B domain of HMGB1; this CD52-HMGB1 complex then promotes binding of the CD52 N-linked glycan (α-2,3 sialic acid linked to galactose) to Siglec-10. This triggers tyrosine phosphorylation of Siglec-10, recruitment of SHP1 phosphatase to Siglec-10's ITIM, and interaction of Siglec-10 with the TCR, suppressing T cell function. CD52-Fc binding assays to Siglec-10 and HMGB1 domains, anti-HMGB1 antibody blockade, co-immunoprecipitation (CD52-HMGB1-Siglec-10-SHP1-TCR complex), tyrosine phosphorylation assay Proceedings of the National Academy of Sciences of the United States of America High 29997173
2019 Tumor-expressed CD24 engages Siglec-10 on tumor-associated macrophages to promote immune evasion; genetic ablation or antibody blockade of either CD24 or Siglec-10 robustly augments macrophage phagocytosis of human tumors expressing CD24. In vivo, CD24 or Siglec-10 blockade resulted in macrophage-dependent reduction of tumor growth. Genetic ablation (CRISPR knockout of CD24 or Siglec-10), monoclonal antibody blockade, phagocytosis assays, in vivo xenograft mouse models Nature High 31367043
2020 Structural and biophysical analysis of Siglec-10 interactions with naturally occurring sialoglycans provided the first molecular insights into ligand recognition; spectroscopic (NMR), computational, and biophysical approaches defined glycan epitope mapping and 3D complex conformations of Siglec-10 with sialoglycans. NMR spectroscopy, computational modeling, biophysical binding assays (STD-NMR, molecular dynamics) iScience Medium 32629603
2020 A GBS-associated rare variant encoding R47Q substitution in the ligand-binding domain of Siglec-10 impairs binding to gangliosides; homology modeling showed marked alteration of the ligand-binding site, indicating that Siglec-10 suppresses antibody production to gangliosides and defects in its function predispose to Guillain-Barré syndrome. Recombinant Siglec-10 protein binding assays, rare variant analysis, homology modeling of ligand-binding site Journal of autoimmunity Medium 33223341
2023 PU.1 transcription factor directly targets and drives Siglec-10 expression in macrophages; PU.1 knockdown reduces Siglec-10 levels, enhances macrophage phagocytosis, and inhibits glioma tumor formation in vivo, establishing a PU.1–Siglec-10 axis in macrophage immune checkpoint regulation. PU.1 knockdown (RNA-seq, qRT-PCR, Western blot), luciferase assay, chromatin immunoprecipitation (ChIP), flow cytometry, in vivo tumor models International immunopharmacology Medium 41115355
2024 Bacterial pseudaminic acid (Pse) on pathogen exopolysaccharide engages Siglec-10 on macrophages via the 7-N-acetyl group of Pse; this interaction stimulates macrophages to secrete IL-10 and suppresses phagocytosis against bacteria. Carbohydrate-receptor binding assay (identifying critical 7-N-acetyl group), IL-10 secretion assay, phagocytosis assay, blocking experiment with Pse-binding protein Chemical communications Medium 38372418
2024 CLL cells suppress CAR T-cell function via CD24 and CD52 — Siglec-10 ligands — expressed on their surface; CD40 stimulation of CLL cells downregulated CD24 and CD52 (prevented by the SRC kinase inhibitor dasatinib), and blocking CD24 and/or CD52 markedly reduced CAR T-cell dysfunction in coculture, demonstrating that CLL-T cell interaction through Siglec-10 ligands mediates T-cell suppression. Co-culture assays, CD40 stimulation, SRC kinase inhibitor (dasatinib) experiments, transcriptome profiling, CD24/CD52 blocking antibodies, flow cytometry Blood advances Medium 39042920
2025 Integrin α3β1 (composed of ITGA3 and ITGB1) on PDAC cells is a sialylated glycoprotein ligand for Siglec-10 on tumor-associated macrophages; the Siglec-10–α3β1 interaction suppresses macrophage phagocytosis, and disruption with monoclonal antibodies restores phagocytosis, reduces PDAC tumor growth in xenograft and Siglec-10 transgenic mouse models. Ligand identification, Co-IP/pulldown, monoclonal antibody blockade, phagocytosis assays, PDAC xenograft and transgenic mouse models Cancer research High 41182080
2026 Crystal structures of Siglec-10 bound to sialyllactose (SL) ligands revealed that domain 1 (D1) engages SL using a non-conserved, selectivity-determining CC' loop; Siglec-10 binds α2,3- and α2,6-linked SL with similar affinities. Homodimerization of Siglec-10 is mediated by a hydrophobic domain 2 (D2) interface, and mutation of this interface ablates cellular binding similarly to mutations in the glycan-binding site. Knockout of CD24 did not affect binding to breast cancer cells, indicating Siglec-10 has a broader glycoprotein recognition profile. X-ray crystallography, mutagenesis of CC' loop and D2 interface, cellular binding assays, CD24 knockout Structure High 41747717
2025 X-ray crystallography of Siglec-10 identified two arginine residues in the binding site (canonical R119 and non-canonical R127) that interact with the carboxyl group of sialic acid; STD-NMR confirmed R119 is essential for binding sialoglycans in solution, while cell-based assays showed both R119 and R127 are critical for cellular glycocalyx recognition. CD24 was ruled out as a principal Siglec-10 ligand on T cells and breast cancer cells, despite high CD24 expression. X-ray crystallography, STD-NMR, site-directed mutagenesis (R119A, R127A), cell-based binding assays with primary human T cells and engineered monocytic lines bioRxivpreprint Medium bio_10.1101_2025.06.10.658867
2024 Molecular dynamics simulations defined atomistic interactions between CD52 glycans, HMGB1 Box B domain, and Siglec-10; O-glycosylation of CD52 was localized to T8, and terminal α-2,3-linked sialic acids on the N-linked glycan were confirmed essential for Siglec-10 binding and T-cell suppression. High-resolution mass spectrometry (glycopeptide/released glycan characterization), molecular dynamics simulation, O-glycosylation site mapping bioRxivpreprint Medium bio_10.1101_2024.10.24.620132

Source papers

Stage 0 corpus · 53 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2019 CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature 1084 31367043
2009 CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science (New York, N.Y.) 666 19264983
2013 T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10. Nature immunology 162 23685786
2001 Identification, characterization and leucocyte expression of Siglec-10, a novel human sialic acid-binding receptor. The Biochemical journal 98 11284738
2001 A new siglec family member, siglec-10, is expressed in cells of the immune system and has signaling properties similar to CD33. European journal of biochemistry 82 11733002
2020 Molecular Mechanism of Tumor Cell Immune Escape Mediated by CD24/Siglec-10. Frontiers in immunology 80 32765491
2001 Cloning and characterization of Siglec-10, a novel sialic acid binding member of the Ig superfamily, from human dendritic cells. The Journal of biological chemistry 77 11358961
2009 Human Siglec-10 can bind to vascular adhesion protein-1 and serves as its substrate. Blood 75 19861682
2018 CD52 glycan binds the proinflammatory B box of HMGB1 to engage the Siglec-10 receptor and suppress human T cell function. Proceedings of the National Academy of Sciences of the United States of America 68 29997173
2014 Pseudaminic acid on Campylobacter jejuni flagella modulates dendritic cell IL-10 expression via Siglec-10 receptor: a novel flagellin-host interaction. The Journal of infectious diseases 66 24823621
2014 Siglec-10 is associated with survival and natural killer cell dysfunction in hepatocellular carcinoma. The Journal of surgical research 60 25450598
2023 Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy. Journal for immunotherapy of cancer 51 37344099
2021 Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma. Experimental hematology & oncology 51 34112250
2016 Expression of CD24 and Siglec-10 in first trimester placenta: implications for immune tolerance at the fetal-maternal interface. Histochemistry and cell biology 46 28012129
2024 Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions. Cancer immunology, immunotherapy : CII 45 38279998
2023 Nano-LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec-10 Signaling Pathway. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 43 36866919
2003 Molecular analysis of human Siglec-8 orthologs relevant to mouse eosinophils: identification of mouse orthologs of Siglec-5 (mSiglec-F) and Siglec-10 (mSiglec-G). Genomics 43 14559209
2022 GATA3 Encapsulated by Tumor-Associated Macrophage-Derived Extracellular Vesicles Promotes Immune Escape and Chemotherapy Resistance of Ovarian Cancer Cells by Upregulating the CD24/Siglec-10 Axis. Molecular pharmaceutics 34 36547230
2019 Malignant ascite-derived extracellular vesicles inhibit T cell activity by upregulating Siglec-10 expression. Cancer management and research 31 31534365
2017 Molecular cloning of porcine Siglec-3, Siglec-5 and Siglec-10, and identification of Siglec-10 as an alternative receptor for porcine reproductive and respiratory syndrome virus (PRRSV). The Journal of general virology 30 28742001
2020 Siglec-10 expression is up-regulated in activated human CD4+ T cells. Human immunology 29 32046870
2020 Unveiling Molecular Recognition of Sialoglycans by Human Siglec-10. iScience 28 32629603
2002 Cloning of two new splice variants of Siglec-10 and mapping of the interaction between Siglec-10 and SHP-1. Biochemical and biophysical research communications 27 12163025
2018 Preferential use of Siglec-1 or Siglec-10 by type 1 and type 2 PRRSV strains to infect PK15S1-CD163 and PK15S10-CD163 cells. Veterinary research 23 30021620
2023 Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer. Journal for immunotherapy of cancer 20 37935567
2022 Innate immune checkpoint Siglec10 in cancers: mining of comprehensive omics data and validation in patient samples. Frontiers of medicine 16 35075579
2023 SLG2 specifically regulates grain width through WOX11-mediated cell expansion control in rice. Plant biotechnology journal 15 37340997
2001 Molecular characterization, tissue expression, and mapping of a novel Siglec-like gene (SLG2) with three splice variants. Biochemical and biophysical research communications 15 11409878
2024 T-cell dysfunction in CLL is mediated through expression of Siglec-10 ligands CD24 and CD52 on CLL cells. Blood advances 14 39042920
2020 A Guillain-Barré syndrome-associated SIGLEC10 rare variant impairs its recognition of gangliosides. Journal of autoimmunity 14 33223341
2024 Identification of Siglec-10 as a new dendritic cell checkpoint for cervical cancer immunotherapy. Journal for immunotherapy of cancer 13 39209455
2014 Molecular characterization of porcine Siglec-10 and analysis of its expression in blood and tissues. Developmental and comparative immunology 13 25280627
2024 Unravelling CD24-Siglec-10 pathway: Cancer immunotherapy from basic science to clinical studies. Immunology 12 39129256
2023 SIGLEC10+ macrophages drive gastric cancer progression by suppressing CD8+ T cell function. Cancer immunology, immunotherapy : CII 12 37432407
2025 Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors. Journal for immunotherapy of cancer 8 40169285
2024 Bacterial pseudaminic acid binding to Siglec-10 induces a macrophage interleukin-10 response and suppresses phagocytosis. Chemical communications (Cambridge, England) 7 38372418
2024 Chitinase 3-like-1 Inhibits Innate Antitumor and Tissue Remodeling Immune Responses by Regulating CD47-SIRPα- and CD24-Siglec10-Mediated Phagocytosis. Journal of immunology (Baltimore, Md. : 1950) 6 39291933
2021 Elevated CD19+Siglec-10+ B cell levels are correlated with systemic lupus erythematosus disease activity. International immunopharmacology 5 34857478
2026 Targeting Interactions Between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer. Cancer research 3 41182080
2025 Targeting Siglec-10/α3β1 Integrin Interactions Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer. bioRxiv : the preprint server for biology 3 40654843
2025 Signal Transducer Nanoparticles Enable Siglec-10/G Blockade Immunotherapy for Breast Cancer Treatment. Advanced materials (Deerfield Beach, Fla.) 2 40619860
2025 Progression of glioma through PU.1-mediated suppression of macrophage phagocytosis via targeting Siglec-10. International immunopharmacology 1 41115355
2025 Circulating CD24/Siglec-10 biomarkers predict post-resuscitation outcomes in a cardiac arrest cohort. Scientific reports 1 41162542
2024 Expression of the mucin-like glycoprotein CD24 and its ligand siglec-10 in placentas with acute and post SARS-CoV-2 infection. Journal of reproductive immunology 1 39612561
2024 The expression of Siglec-10 on naive B cells is involved in the pathology of systemic lupus erythematosus. Clinical and experimental rheumatology 1 39711368
2026 Mitoxantrone alters CD24/Siglec-10 expression in malignant brain tumor models. Scientific reports 0 41606146
2026 Structural basis for sialoglycan recognition by the immune inhibitory receptor Siglec-10. Structure (London, England : 1993) 0 41747717
2026 Chemoradiotherapy facilitates siglec-10+/siglec-9+ macrophage-mediated impairment of CD24+/MUC16+ tumor cell elimination and enhances PD-L2 dependent immunosuppression in cervical cancer. Cancer immunology, immunotherapy : CII 0 41801406
2026 Accumulation of Siglec10+CX3CR1+ Macrophages in the Tumor Microenvironment of Glioblastomas. European journal of immunology 0 42003504
2025 Commentary on "Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors". Journal for immunotherapy of cancer 0 40518291
2025 First Evidence of Siglec-10 Localization and Expression in Camel Male Reproductive Tissues and Spermatozoa: Potential Relevance to Fertility. Veterinary sciences 0 41295701
2025 Nebulized macrophage membrane-engineered triptolide liposomes for Siglec-10/CD24-mediated therapeutic targeting in lung cancer. International journal of pharmaceutics: X 0 41404373
2023 High Expression and Significance of Siglec10/CD24 in Unexplained Missed Abortion. Immunological investigations 0 37933581